Inclusion of this agent is supported by data from a phase 1 study (NANT 1502, NCT03107988) in which patients with ALK aberrant recurrent or refractory neuroblastoma tolerated the combination of lorlatinib with chemotherapy and demonstrated a clinical response [29]. The gene discussed is ALK; the disease is neuroblastoma.